Comparative Pharmacology
Head-to-head clinical analysis: ETHMOZINE versus SOTYLIZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHMOZINE versus SOTYLIZE.
ETHMOZINE vs SOTYLIZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ic antiarrhythmic; blocks cardiac sodium channels, slowing phase 0 depolarization and reducing conduction velocity in atrial and ventricular myocardium.
Selective beta-1 adrenergic receptor antagonist; also exhibits class III antiarrhythmic activity (potassium channel blockade), prolonging cardiac repolarization and refractory periods.
200-300 mg orally every 8 hours; maximum 900 mg/day.
Initial: 80 mg orally twice daily. May increase every 2-3 days in 40-80 mg increments up to 240-320 mg/day. Maximum: 320 mg/day in divided doses.
None Documented
None Documented
3-12 hours (mean ~6 hours); prolonged in hepatic or renal impairment.
Terminal elimination half-life is 12-16 hours in patients with normal renal function; can extend up to 30-40 hours in renal impairment, requiring dose adjustment.
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for <1% of a dose; approximately 10-20% excreted in feces via bile.
Primarily renal excretion of unchanged drug; 85-90% eliminated unchanged in urine, with the remainder via feces (<5%) and minimal biliary excretion.
Category C
Category C
Antiarrhythmic
Antiarrhythmic